Intrathecal Baclofen for Severe Spasticity: Longitudinal Data From the Product Surveillance Registry.
Mya Caryn SchiessSam S EldabePeter KonradLisa MolusRobert SpencerKatherine StrombergTodd WeaverRobert PlunkettPublished in: Neuromodulation : journal of the International Neuromodulation Society (2020)
ITB therapy for the treatment of severe spasticity requires surgical implantation of a programmable infusion system for chronic drug delivery. If complications arise, many necessitate surgical intervention for correction. For spinal and cerebral spasticity in pediatric and adult patients, discontinuation rates due to an adverse event were low (0.3%), and there was high acceptance (99.1%) of surgical intervention for therapy continuation. Patient/caregiver willingness to accept surgical and other risks for therapy continuation was extremely high.
Keyphrases
- spinal cord injury
- drug delivery
- randomized controlled trial
- botulinum toxin
- upper limb
- public health
- spinal cord
- early onset
- emergency department
- cerebral palsy
- subarachnoid hemorrhage
- risk factors
- cross sectional
- big data
- adverse drug
- drug induced
- risk assessment
- climate change
- bone marrow
- blood brain barrier
- mesenchymal stem cells
- replacement therapy
- drug release